Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31263361 | 0.79 | LMNA (0.38) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL19565571 | 0.73 | LMNA (0.40) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL19565573 | 0.73 | LMNA (0.40) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL29224293 | 0.73 | ALDH1A1 (0.35) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL19318890 | 0.69 | MAPT (0.39) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL422879 | 0.69 | MAPT (0.46) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8647198 | 0.69 | MAPT (0.39) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL16409442 | 0.69 | LMNA (0.41) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL16700910 | 0.67 | CYP3A4 (0.43) | LMNAALDH1A1MAPTCYP3A4CYP2D6 | |
| SCHEMBL8462991 | 0.67 | ALDH1A1 (0.40) | LMNAPPM1BPTPN1PPP1CCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | LMNA 3767/4885PPM1B 2844/4885PTPN1 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.